Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
Stocks · News reference
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.34) by 82.35 percent. This is a 88.46 percent increase over losses of $(0.52) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
8-K filing — Unicycive Therapeutics, Inc. (UNCY)
Filed: 2026-08-12 AccNo: 0001213900-26-088061 Size: 279 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits